Banerjee, R., Richards, A., Midha, S., Afrough, A., Anwer, F., Atanackovic, D., Atrash, S., Bachanova, V., Beitinjaneh, A. M., Ouchveridze, E., Castaneda Puglianini, O., Chhabra, S., Cicero, K. I., Davis, J. A., Dhakal, B., Dima, D., Ferreri, C. J., Forsberg, P. A., Freeman, C. L., … Kaur, G. (2025). Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016131

Gao, S., Bassil, D. T., Wagner, R. G., du Toit, J., Huber, H., Ashton, N. J., Cotton‐Samuel, D., Farrell, M. T., Mngomezulu, V., Manly, J. J., Tollman, S., Berkman, L. F., Zetterberg, H., & Brickman, A. M. (2024). Assessing the feasibility of dried blood spot (DBS) collection for blood‐based biomarkers of Alzheimer’s Disease in rural South Africa. Alzheimer’s & Dementia, 20(S2). Portico. https://doi.org/10.1002/alz.092596

Davar, D., Williams, A., Lopez, J., Olson, D., Sato, T., Shaw, H., Friedman, C. F., Thistlethwaite, F., Middleton, M., Lebbe, C., Ma, V. T., Izar, B., Lau, P., Bechter, O., Kirk, P., Yuan, Y., Marshall, S., & Hamid, O. (2024). 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Regular and Young Investigator Award Abstracts, A796–A796. https://doi.org/10.1136/jitc-2024-sitc2024.0694

Winter, H., Baldassano, R. N., Pfeffkorn, M. D., Wali, P., Verstraete, S. G., Picoraro, J. A., Washek, M. A., Kumar, N., Mortan, W., Havard- Jr, M., Blystone, L., Trombler, B., Pursley, C., Lin, X., Dillon, S. T., Gu, X., Otu, H. H., Ngo, L., & Libermann, T. A. (2024). P192 Personalizing treatment for predicting response to infliximab in children with Crohn’s disease using proteomic biomarkers. Journal of Crohn’s and Colitis, 18(Supplement_1), i506–i506. https://doi.org/10.1093/ecco-jcc/jjad212.0322

Theodore, D., Neradilek, M., Gillespie, K., Edupuganti, S., Hinojosa, J. C., Lama, J. R., De La Grecca, R., Davis, A., Mangini, D. J., Andrew, P., Marovich, M., Zwerski, S., Castor, D., Roxby, A. C., Cohen, M., Corey, L., Huang, Y., Karuna, S., & Sobieszczyk, M. E. (2023). 1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085. Open Forum Infectious Diseases, 10(Supplement_2). https://doi.org/10.1093/ofid/ofad500.1393

Midha, S., Gurumurthi, A., Costello, P., Redd, R. A., Freeman, C. L. L., Castaneda, O., Gonzalez, R., Ionescu, F., Gaballa, M., Kalariya, N., Khouri, J., Dima, D., Kocoglu, M. H., Sborov, D., Wagner, C. B., Atrash, S., Voorhees, P. M., Hashmi, H., Davis, J. A., … Patel, K. K. (2023). Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. Blood, 142(Supplement 1), 3499–3499. https://doi.org/10.1182/blood-2023-187565

Mejia Saldarriaga, M., Unkenholz, C., Fein, J. A., Monge, J., Rosenbaum, C., Pearse, R., Mapara, M., Inghirami, G., Lentzsch, S., Reshef, R., Niesvizky, R., & Bustoros, M. (2023). Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities. Blood, 142(Supplement 1), 3341–3341. https://doi.org/10.1182/blood-2023-187832

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Peng, W., Lui, C., Wulff, J., … Jacobson, C. A. (2023). Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood, 142(Supplement 1), 4868–4868. https://doi.org/10.1182/blood-2023-174914

Mena Lora, A. J., Long, J. E., Huang, Y., Baden, L. R., El Sahly, H. M., Follmann, D., Goepfert, P., Gray, G., Grinsztejn, B., Kotloff, K., Rouphael, N., Sobieszczyk, M., Walsh, S. R., Andriesen, J., Shah, K. A., Zhang, Y., Gilbert, P., Janes, H., Gay, C. L., … Wallace, S. E. (2023). Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Network Open, 6(1), e2251974. https://doi.org/10.1001/jamanetworkopen.2022.51974